NCT01440803View on ClinicalTrials.gov

Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 2, 2012

Primary Completion Date

January 1, 2018

Study Completion Date

February 1, 2019

Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
DRUG

Teriparatide

Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.

DRUG

Saline Placebo

Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.

Trial Locations (2)

10032

Columbia University Medical Center, New York

68131

Creighton University, Omaha

All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

lead

Elizabeth Shane

OTHER

NCT01440803 - Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women | Biotech Hunter | Biotech Hunter